VIVACTIL (protriptyline hydrochloride) by Teva is clinical pharmacology protriptyline hydrochloride is an antidepressant agent. Approved for symptoms of mental depression in patients. First approved in 1967.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
VIVACTIL (protriptyline hydrochloride) is a tricyclic antidepressant approved in 1967 for treatment of symptoms of mental depression. It works through an unknown mechanism that does not involve monoamine oxidase inhibition, with a notably rapid onset of action within one week compared to peer agents. The drug lacks significant sedative properties and exhibits slow excretion kinetics.
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling a consolidated, efficiency-focused team structure rather than growth-phase expansion.
CLINICAL PHARMACOLOGY Protriptyline hydrochloride is an antidepressant agent. The mechanism of its antidepressant action in man is not known. It is not a monoamine oxidase inhibitor, and it does not act primarily by stimulation of the central nervous system. Protriptyline has been found in some…
Working on VIVACTIL offers limited career advancement potential, as the product faces imminent loss of exclusivity in a mature, declining market segment. Roles are primarily defensive and operationally focused, emphasizing cost management and market share retention rather than growth or innovation.
Worked on VIVACTIL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.